Luminus10 mg

Luminus is a leukotriene receptor antagonist used for the following FDA-approved indications:

• Prophylaxis and chronic treatment of asthma in adults and children 12 months of age and older (established, first-line/add-on maintenance therapy).
• Relief of symptoms of seasonal allergic rhinitis in adults and children 2 years of age and older (established use).
• Relief of symptoms of perennial allergic rhinitis in adults and children 6 months of age and older (established use).
• Prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older (established use; used as-needed before exertion, not as maintenance monotherapy for this indication alone).

Luminus is often used as an adjunct/add-on to inhaled corticosteroids when asthma control is inadequate, and it is a guideline-recognized alternative (not first-line) controller option in patients who cannot or will not use inhaled corticosteroids.

Important: Luminus is not indicated for the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. It has no role as a rescue medication.

Each tablet/chewable tablet/sachet of oral granules contains Montelukast Sodium equivalent to the labelled strength of montelukast (commonly available as 4 mg oral granules, 4 mg and 5 mg chewable tablets, and 10 mg film-coated tablets), along with pharmaceutically acceptable excipients.

Luminus is an orally active, selective leukotriene receptor antagonist (LTRA) belonging to the class of anti-asthmatic and anti-allergic medicines. It is used for the long-term control (not immediate relief) of asthma symptoms and for the relief of symptoms of allergic rhinitis.

Unlike bronchodilators, Luminus works by blocking the action of leukotrienes, inflammatory chemical mediators involved in airway narrowing, mucus production, and allergic inflammation, and is intended for regular, once-daily use rather than as-needed symptom relief (except when used specifically before exercise for EIB prevention).

Luminus belongs to the therapeutic class of Leukotriene Receptor Antagonists (LTRAs), also broadly categorized under anti-asthmatic and anti-allergic (anti-rhinitis) agents.

Montelukast Sodium is a selective and orally active antagonist of the cysteinyl leukotriene CysLT1 receptor. Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory mediators released from mast cells and eosinophils that bind to CysLT1 receptors in the human airway, producing bronchoconstriction, increased vascular permeability, mucus secretion, and eosinophil recruitment.

By blocking the CysLT1 receptor, Montelukast Sodium inhibits these leukotriene-mediated effects, thereby reducing airway inflammation and improving airflow in asthma, and reducing nasal congestion, sneezing, and rhinorrhea in allergic rhinitis. Montelukast Sodium does not have direct bronchodilator activity and does not act on histamine receptors.

After oral administration, montelukast is rapidly absorbed with high oral bioavailability (film-coated tablet), is highly bound to plasma proteins (>99%), is extensively metabolized in the liver primarily via CYP3A4 and CYP2C8 (with a minor role for CYP2C9), and is eliminated almost entirely via biliary excretion, with a plasma half-life of approximately 2.7 to 5.5 hours in healthy adults.

• Luminus tablets/chewable tablets/granules may be taken with or without food.
• Film-coated tablets should be swallowed whole with water; they should not be crushed or chewed.
• Chewable tablets must be chewed, not swallowed whole, particularly in young children.
• Oral granules may be administered directly in the mouth, or mixed with a spoonful of cold or room-temperature soft food (e.g., mashed carrots, ice cream) or dissolved in a spoonful of breast milk or infant formula. The granules must not be dissolved in any liquid other than breast milk or infant formula for drinking, and once the packet is opened, the full dose must be administered within 15 minutes.
• For chronic conditions (asthma, allergic rhinitis), Luminus should be taken regularly every day, in the evening, even during symptom-free periods, as directed by the physician.
• For EIB prevention only, a single dose is taken at least 2 hours before exercise, and patients already on a regular evening dose for asthma/rhinitis should not take an additional dose for exercise.

Luminus has the following clinically relevant drug interactions:

• Strong CYP450 enzyme inducers (e.g., phenobarbital, rifampin): Co-administration can substantially lower plasma concentrations of Luminus (rifampin has been shown to reduce montelukast exposure by roughly 40%), potentially reducing efficacy; clinical monitoring is advised if used together.
• Gemfibrozil (a CYP2C8 inhibitor): Increases plasma concentrations of Luminus; while a specific dose adjustment is not established, monitor for increased adverse effects.

No clinically significant interactions requiring dose adjustment have been demonstrated between Luminus and theophylline, warfarin, digoxin, oral contraceptives, or oral corticosteroids/prednisone at recommended doses.

Common side effects of Luminus (occurring in clinical trials) include headache, abdominal pain, cough, dyspepsia, dizziness, fatigue, fever, and, in children, ear infection (otitis media), sinusitis, and influenza-like symptoms.

Serious but less common effects include neuropsychiatric events (see Precautions and Warnings for the boxed warning), hepatic effects such as eosinophilic hepatitis (rare), hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, and rare severe skin reactions (Stevens-Johnson syndrome, erythema multiforme), and rare eosinophilic conditions such as Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis), particularly in patients whose oral corticosteroid dose is being reduced (see Precautions and Warnings).

Pregnancy: Available human data (including pregnancy registry and observational data) have not shown a clear association between Luminus use in pregnancy and major birth defects. However, as with any medicine in pregnancy, Luminus should be used during pregnancy only if clearly needed, and only if the potential benefit to the mother justifies the potential risk to the fetus. A physician should be consulted before use in pregnancy.

Lactation: Montelukast passes into breast milk in animal studies; limited human data are available. A physician should be consulted to weigh the benefits of treatment against any potential risk to the breastfed infant before using Luminus during breastfeeding.

Boxed Warning: Neuropsychiatric Events

Luminus carries a boxed warning for neuropsychiatric events. Postmarketing reports with Luminus include agitation, aggression, anxiousness, abnormal dreams, hallucinations, depression, insomnia, irritability, restlessness, tremor, and suicidal thoughts and behavior (including completed suicide). Patients and caregivers should be advised to be alert for new or worsening mood or behavior changes and to contact the prescriber promptly if these occur. Given the availability of alternative therapies for allergic rhinitis, prescribers should carefully weigh the risks and benefits of Luminus before prescribing it, especially for allergic rhinitis alone.

Other Precautions

• Luminus is not a bronchodilator and is not intended to treat acute asthma attacks; patients should be instructed to keep their usual rescue (fast-acting) inhaler available for acute symptoms and to seek medical attention for worsening asthma or an acute attack.
• Luminus does not affect aspirin-sensitivity reactions; patients with known aspirin or NSAID sensitivity should continue to avoid these agents while taking Luminus.
• Oral or inhaled corticosteroid therapy should not be abruptly reduced or discontinued when starting Luminus; any reduction in systemic corticosteroid dose should be done gradually under medical supervision, since a rare eosinophilic condition (Churg-Strauss syndrome/eosinophilic granulomatosis with polyangiitis) has been reported in this setting.
• Chewable tablet formulations of Luminus may contain aspartame (a source of phenylalanine) and should be used with caution in patients with phenylketonuria (PKU).
• Rare cases of liver dysfunction have been reported; patients should be advised to report symptoms such as yellowing of the skin/eyes, dark urine, or unusual fatigue.

Reported symptoms of Luminus overdose include thirst, drowsiness, mydriasis (dilated pupils), hyperkinesia (restlessness/increased activity), and abdominal pain, generally without serious clinical consequences at reported doses. There is no specific antidote for Luminus overdose.

In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services. Management is supportive and symptomatic; it is not known whether montelukast is removed by peritoneal dialysis or hemodialysis.

Store at room temperature (below 30°C), away from light and moisture, in the original package. Once opened, oral granule packets must be used within 15 minutes. Keep out of reach of children.

• Pediatric use: The safety and efficacy of Luminus have been established for asthma in children as young as 12 months (granules), for perennial allergic rhinitis from 6 months, for seasonal allergic rhinitis from 2 years, and for EIB prevention from 6 years. Safety and efficacy have not been established below these respective age cut-offs for each indication.
• Geriatric use: Clinical studies of Luminus did not identify overall differences in safety or effectiveness between elderly and younger patients; no dosage adjustment is required based on age alone, though the possibility of greater sensitivity in some older individuals cannot be ruled out.
• Renal impairment: No dosage adjustment of Luminus is required.
• Hepatic impairment: No dosage adjustment is required in mild-to-moderate hepatic impairment; use with caution in severe hepatic impairment as this population has not been studied.

For chronic asthma control and allergic rhinitis, Luminus is intended for regular, long-term, once-daily use as directed by the physician, including during symptom-free periods, since its benefit depends on continuous leukotriene receptor blockade rather than on-demand symptom relief. Improvement in asthma control can be seen within one day of starting treatment, but the physician should periodically reassess ongoing need and response. For prevention of exercise-induced bronchoconstriction, treatment is a single dose taken before each anticipated exercise session rather than a fixed "course" of therapy.

Leukotriene Receptor Antagonist (LTRA); Anti-asthmatic and anti-allergic agent.

Montelukast Sodium selectively and competitively antagonizes the cysteinyl leukotriene receptor CysLT1, which mediates the bronchoconstrictive, mucus-secretory, vaso-permeability, and eosinophil-chemotactic effects of cysteinyl leukotrienes (LTC4, LTD4, LTE4) released during allergic and asthmatic inflammatory responses. By blocking this receptor, Montelukast Sodium reduces airway inflammation and symptoms without producing direct bronchodilation.

B (legacy FDA pregnancy category, assigned prior to the 2015 Pregnancy and Lactation Labeling Rule)

Luminus is approved for use in specific pediatric age groups depending on indication: from 12 months of age for asthma (as oral granules), from 6 months of age for perennial allergic rhinitis, from 2 years of age for seasonal allergic rhinitis, and from 6 years of age for prevention of exercise-induced bronchoconstriction. Dosing is age- and formulation-specific (oral granules, chewable tablets, or film-coated tablets); parents/caregivers should be counseled on the correct formulation and administration technique for the child's age. Safety and efficacy of Luminus have not been established in children younger than these approved age thresholds for each respective indication. Caregivers should be specifically counseled about the boxed warning for neuropsychiatric events, including in children, and told to report any new mood, behavior, or sleep changes promptly.